drugset / Trial / NCT02550548

Incretin Action in Physiology and Diabetes

NCT02550548

Non-randomizedParallel-groupSingle-blindBasic science

Summary

This project is designed to advance understanding of the incretin effect in health and disease. This system of gut-islet linkage is essential for normal glucose tolerance, impaired in T2DM, and amenable to therapeutic intervention. However, there are important gaps in understanding incretin function that limit application of this system; this project will address several of these. A secondary, but critical aspect of this research is focus on inter-individual variation in the physiology of the incretin system. This is a novel direction for research in this field and is critical to advancing the concept of individualized medical care in diabetes by establishing whether there is a physiologic basis for predicting the existence of responders and non-responders to incretin therapies. Currently, we have described only Aim 1 from this grant in this protocol registration. While Aim 2 and 3 are described in the grant, Aim 1 will be conducted first and the results from this Aim and / or the publication of other results in the field may affect the approach to Aims 2 and 3.

Timeline

Start
2016-04-21
Primary completion
2021-04-16
Completion
2021-04-16

Drugs

EvaluationDrugModalityDoseRoute
Subject Ex-9 Unknown 2.5 ug/kg Other
Subject GIP Unknown 0.001 ug/kg Other
Subject GIP Unknown 0.002 ug/kg Other
Subject GIP Unknown 0.004 ug/kg Other
Subject GIP Unknown 0.008 ug/kg Other
Subject GIP Unknown 0.016 ug/kg Other
Subject GLP-1 Peptide 0.0005 ug/kg Other
Subject GLP-1 Peptide 0.001 ug/kg Other
Subject GLP-1 Peptide 0.0015 ug/kg Other
Subject GLP-1 Peptide 0.002 ug/kg Other
Subject GLP-1 Peptide 0.003 ug/kg Other
Subject GLP-1 Peptide 0.004 ug/kg Other